Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Perioperative chemotherapy remains the standard-of-care for resectable gastric and gastroesophageal junction (G/GEJ) adenocarcinoma, yet pathologic complete response (pCR) rates remain low and long-term survival is suboptimal. Apatinib has shown efficacy in advanced G/GEJ cancer, but its role and optimal combination regimens in the neoadjuvant setting remain unclear, and no quantitative evidence synthesis has been published.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
